BioCryst Pharmaceuticals | BCRX - Interest Expense On Debt


BioCryst Pharmaceuticals reported $14.14M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Chugai Pharma JPY 95M 260M Dec/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
DBV Technologies USD 461K 323.71K Mar/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 167M 21M Mar/2026
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novavax USD 5.82M 342K Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025